Perspective Therapeutics (CATX) Liabilities and Shareholders Equity (2011 - 2026)

Perspective Therapeutics has reported Liabilities and Shareholders Equity for 16 years, with the latest figure at $410.8 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 24.72% year-over-year to $410.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (down 11.35% YoY) and the FY2025 annual result came in at $267.0 million, down 21.73% from the prior year.
• Liabilities and Shareholders Equity improved to $410.8 million in Q1 2026 per CATX's latest filing, from $267.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $410.8 million in Q1 2026 and troughed at $58.1 million in Q4 2022.
• A 5-year average of $218.6 million and a median of $267.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity surged 253.93% in 2024, then dropped 24.63% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $58.1 million in 2022, then surged by 68.51% to $97.9 million in 2023, then jumped by 248.45% to $341.1 million in 2024, then declined by 21.73% to $267.0 million in 2025, then jumped by 53.86% to $410.8 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $410.8 million, $267.0 million, and $294.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.